Tissue Regenix Group plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRX.L research report →
Companywww.tissueregenix.com
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, and GBM-V & Cardiac divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth.
- CEO
- Jay Charles LeCoque
- IPO
- 2006
- Employees
- 82
- HQ
- Garforth, GB
Price Chart
Valuation
- Market Cap
- $5.16M
- P/E
- -7.09
- P/S
- 0.50
- P/B
- 0.23
- EV/EBITDA
- 3369.28
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 41.82%
- Op Margin
- -3.52%
- Net Margin
- -6.77%
- ROE
- -3.16%
- ROIC
- -1.22%
Growth & Income
- Revenue
- $28.65M · -2.87%
- Net Income
- $-713,000 · 58.38%
- EPS
- $-0.01 · 58.44%
- Op Income
- $349.00K
- FCF YoY
- -3322.60%
Performance & Tape
- 52W High
- $66.00
- 52W Low
- $4.77
- 50D MA
- $21.12
- 200D MA
- $34.25
- Beta
- 0.39
- Avg Volume
- 394.90K
Get TickerSpark's AI analysis on TRX.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TRX.L Coverage
We haven't published any research on TRX.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TRX.L Report →